Exenatide Inhibits the K<sub>Ca</sub>3.1 Channels of Aortic Vascular Smooth Muscle in Diabetic Rats.
Acta Cardiol Sin · 2017
Last updated 2026-08-28| Journal | Acta Cardiol Sin, 2017 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.22 |
| NIH percentile | 14 |
| Molecules | exenatide |
Abstract
BACKGROUND: K3.1 ion channels play an important role during atherosclerosis. We aimed to investigate the effect of exenatide on K3.1 expression in aortic vascular smooth muscle cells (VSMCs) of diabetic rats.
METHODS: Sprague-Dawley rats were randomly divided into normal control (NC), diabetes model (DM), and exenatide treatment (ET) groups. Hematoxylin and eosin and α-actin immunohistochemical staining were used to detect changes in rat aortic vascular smooth muscle. Quantitative RT-PCR and Western blot analysis were used to detect changes in K3.1 mRNA and protein levels, respectively.
RESULTS: Aortic tissue staining in the DM group revealed an absence of smooth or integrated endothelium, increased smooth muscle cell proliferation in the media, smooth muscle hyperplasia, disorganized smooth muscle cells, and an increased number of collagen fibers, relative to the NC and ET groups. K3.1 mRNA expression was higher in the DM group than in the NC and ET groups. Similarly, the K3.1 protein level was higher in the DM group than in the NC and ET groups. The K3.1 protein level did not significantly differ between the ET and NC groups.
CONCLUSIONS: Exenatide could inhibit the expression of the K3.1 channel in VSMCs of diabetic rats.
Verbatim abstract via PubMed 29167619 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.